Oncostatin M is a novel glucocorticoid-dependent neuroinflammatory factor that enhances oligodendrocyte precursor cell activity in demyelinated sites


Autoria(s): GLEZER, Isaias; RIVEST, Serge
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

20/10/2012

20/10/2012

2010

Resumo

The innate immune reaction to tissue injury is a natural process, which can have detrimental effects in the absence of negative feedbacks by glucocorticoids (GCs). Although acute lipopolysaccharide (LPS) challenge is relatively harmless to the brain parenchyma of adult animals, the endotoxin is highly neurotoxic in animals that are treated with the GC receptor antagonist RU486. This study investigated the role of cytokines of the gp130-related family in these effects, because they are essential components of the inflammatory process that provide survival signals to neurons. Intracerebral LPS injection stimulated expression of several members of this family of cytokines, but oncostatin M (Osm) was the unique ligand to be completely inhibited by the RU486 treatment. OSM receptor (Osmr) is expressed mainly in astrocytes and endothelial cells following LPS administration and GCs are directly responsible for its transcriptional activation in the presence of the endotoxin. In a mouse model of demyelination, exogenous OSM significantly modulated the expression of genes involved in the mobilization of oligodendrocyte precursor cells (OPCs), differentiation of oligodendrocyte, and production of myelin. In conclusion, the activation of OSM signaling is a mechanism activated by TLR4 in the presence of negative feedback by GCs on the innate immune system of the brain. OSM absence is associated with detrimental effects of LPS, whereas exogenous OSM favors repair response to demyelinated regions. (C) 2010 Elsevier Inc. All rights reserved.

Multiple Sclerosis Society of Canada

Multiple Sclerosis Society of Canada

FAPESP[2008/55645-8]

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

FAPESP[2007/53732-8]

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Canadian Research Chair in Neuroimmunology

Canadian Research Chair in Neuroimmunology

Canadian Institutes of Health Research (CIHR)

Canadian Institutes in Health Research (CIHR)

Neuroscience Canada

Neuroscience Canada

Identificador

Brain, Behavior, and Immunity, v.24, n.5, Special Issue, p.695-704, 2010

0889-1591

http://producao.usp.br/handle/BDPI/31479

10.1016/j.bbi.2010.01.005

http://dx.doi.org/10.1016/j.bbi.2010.01.005

Idioma(s)

eng

Publicador

ACADEMIC PRESS INC ELSEVIER SCIENCE

Relação

Brain, Behavior, and Immunity

Direitos

restrictedAccess

Copyright ACADEMIC PRESS INC ELSEVIER SCIENCE

Palavras-Chave #Brain repair #Demyelination #gp130 #Lipopolysaccharide #Neuroprotection #Olig bHLH transcription factors #Glucocorticoids #INNATE IMMUNE-RESPONSE #CENTRAL-NERVOUS-SYSTEM #ETHIDIUM-BROMIDE INJECTION #NEURONAL SURVIVAL #IN-VIVO #MULTIPLE-SCLEROSIS #SIGNALING PATHWAYS #NEURAL PRECURSORS #MYELIN FORMATION #LIF RECEPTOR #Immunology #Neurosciences
Tipo

article

original article

publishedVersion